BMS and Dr Reddy’s settle Revlimid suit with generics licence

Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

More on this story

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

More on this story

Americas

BMS boosts cardio portfolio with $13bn buy

6 October 2020 Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

Americas

BMS sues over generic of blockbuster leukaemia treatment

4 October 2021 Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

BMS and Dr Reddy’s settle Revlimid suit with generics licence

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features